About Daewoong

Daewoong Pharmaceutical is a global healthcare group that improves the quality of life

Holding Company

  • Daewoong
    Resource management and management support for affiliated companies
    Go to homepage

Daewoong Affiliates

  • Daewoong Pharmaceutical
    Manufacture and sales of finished dose
    Go to homepage
  • Daewoong Bio
    Manufacture and sales of API
    Go to homepage
  • Daewoong Life Science
    Production and sales of health food and life products
    Go to homepage
  • DMD Daewoong Management Development Institute
    Corporate personnel training business
    Go to homepage
  • idsTrust
    Computer, peripheral devices and software development and sales
    Go to homepage
  • Daewoong ENG
    Facility management services and machine production
    Go to homepage
  • Pharm Pack
    Pharmaceutical product packaging professionals
  • Daewoong Development
    Real estate leasing
  • Sanwoong Development
    Facility management services
  • Daewoong Therapeutics
    R&D on first-in-class DR/DDS-based new drugs
    Go to homepage

Daewoong Pharmaceutical Affiliates

  • Hanall Biopharma
    Pharmaceutical product R&D
    Go to homepage
  • MD Well
    Medicine and nutrition company, production and sales of nutritious meals
    Go to homepage
  • Healience Seonmaeul
    New conceptual lifestyle improvement program, and the nation’s first wellness center
    Go to homepage
  • Affyxell Therapeutics
    R&D on pharmaceutical drugs and medicine
    Go to homepage
  • iN Therapeutics
    R&D on pharmaceutical drugs and medicine
affyxell logo
Affyxell Therapeutics
R&D on pharmaceutical drugs and medicine
Establishment
History
CEO: Seng Ho Jeon & Jong Sang Ryu
Date of establishment : February 06, 2020
Headquater: Kimhae, Korea (Kimhae Biomedical Center)
R&D center: Yong In, Korea (Gwanggyo)
Vision
A right of all mankind is a life that is healthy, joyful, and gratifying, free from suffering of illnesses.
Mission
AffyXell provides a new class of affordable cellular therapeutics that help patients recover
from intractable disease and regain their health.
  • DW transfers the platform license and technology
  • DW provides DW-MSC production know-how
  • DW’s MSC development experts (R&D/RA/CMC/Clinical)
  • Affimer performs development and tech transfer
  • Affimer transfers specific target exclusive IP
  • Affimer’s development experts (R&D/Clinical)

Limit 1.

Limitations of Current Stem Cell Therapy

  • icon

    Donor
    variance

  • icon

    High cost
    Low efficacy

  • icon

    Need for
    specific MoA

Limit 2.

Limitations of Current Non-IgG Scaffold

  • icon

    Relatively short
    Half-life
    compared to
    Antibody drugs

  • icon

    Low efficacy
    Compared to
    Competitive
    treatments

  • icon

    Lack of feasible
    New substance

AFX platform : Affimer-encoded Mesenchymal Stem Cells

Overcoming Barriers

Next Generation Cell Therapy (AFX Platform)

Overcoming donor variance by using pluripotent
stem cell-derived MSC

Improved productivity in cell therapy by using pluripotent
stem cell-derived MSC

Securing specific treatment mechanism through
Affimer gene introduction

Synergy through platform convergence
In-body factory : overcoming a short half-life of Affimer Superior efficacy expected compared to
competitor treatments

*Pluripotent stem cell-derived Mesenchymal Stem Cell